Paper Review Records
All Paper Review Records
20 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
71
days
The past, present, and future treatment of BRAF V600 ‐mutant metastatic colorectal cancer: A comprehensive review
AuthorsIris Dirven; Celina Ang; Cleo Bertels; Koen Kortbeek; Amy de Haar‐Holleman; Marieke Vollebergh; Poulikos Poulikakos; Bart Neyns
Affiliations1. Team Laboratory for Medical and Molecular Oncology Translational Oncology Research Center, Department of Medical Oncology, Vrije Universiteit Brussel and Universitair Ziekenhuis Brussel Brussels Belgium; 2. Division of Hematology/Oncology, Department of Medicine Tisch Cancer Institute, Mount Sinai Hospital New York New York USA; 3. Department of Medical Oncology Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital Amsterdam Netherlands; 4. Department of Gastrointestinal Oncology Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital Amsterdam Netherlands; 5. Department of Oncological Sciences The Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York New York USA
109
days
Disease‐free survival as a surrogate outcome for localized kidney cancer—A systematic review and meta‐analysis
AuthorsConstanza Martinez; David Chen; Russell Leong; Nicholas Lum; Karren Xiao; Laith Almasri; Christian K. Kollmannsberger; Srinivas Raman
Affiliations1. Department of Radiation Oncology McGill University Health Center Montreal Quebec Canada; 2. Radiation Medicine Program Princess Margaret Hospital Cancer Center Toronto Ontario Canada; 3. Temerty Faculty of Medicine University of Toronto Toronto Ontario Canada; 4. Faculty of Medicine University of Ottawa Ottawa Ontario Canada; 5. Department of Medical Oncology British Columbia Cancer Vancouver Vancouver British Columbia Canada; 6. Department of Radiation Oncology British Columbia Cancer Vancouver Vancouver British Columbia Canada
89
days
Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings—international expert consensus
AuthorsDaniel J. DeAngelo; Anna Avagyan; Jeanine Alfaro; Valentino Conter; Maria L. de Martino Lee; Łukasz Hutnik; Miriam Hwang; Hiroto Inaba; Atsushi Manabe; Jae H. Park; Rob Pieters; Carmelo Rizzari; Vaskar Saha; David T. Teachey; Inge M. van der Sluis; Scott C. Howard
Affiliations1. Department of Medical Oncology Dana‐Farber Cancer Institute Boston Massachusetts USA; 2. Pediatric Cancer and Blood Disease Center Yeolan Hematology and Oncology Center Yerevan Armenia; 3. Department of Pediatrics Unidad Nacional de Oncología Pediatrica Guatemala City Guatemala; 4. Tettamanti Center IRCCS San Gerardo dei Tintori Monza Italy; 5. Beneficência Portuguesa de São Paulo Sao Paulo Brazil; 6. Pediatric Oncology, Hematology and Clinical Transplantology Medical University of Warsaw Warsaw Poland; 7. Resonance Memphis Tennessee USA; 8. Department of Oncology St Jude Children’s Research Hospital Memphis Tennessee USA; 9. Department of Pediatrics Hokkaido University Graduate School of Medicine Hokkaido Japan; 10. Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA; 11. Princess Máxima Center for Pediatric Oncology Utrecht Netherlands; 12. Pediatric Hematology‐Oncology Unit IRCCS San Gerardo dei Tintori Monza Italy; 13. Division of Cancer Sciences University of Manchester School of Medicine Manchester UK; 14. Center for Childhood Cancer Research Children’s Hospital of Philadelphia Philadelphia Pennsylvania USA; 15. Yeolyan Hematology‐Oncology Center Yerevan Armenia
155
days
How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data
AuthorsStephen J. Freedland; Wei Gao; Maëlys Touya; Hongbo Yang; David Russell; Jingyi Chen; Grace Chen; Jasmina I. Ivanova
Affiliations1. Department of Urology Samuel Oschin Comprehensive Cancer Institute Cedars‐Sinai Medical Center Los Angeles California USA; 2. Durham VA Medical Center Durham North Carolina USA; 3. Analysis Group Inc. Boston Massachusetts USA; 4. Astellas Pharma Global Development Northbrook Illinois USA; 5. Pfizer Inc. New York New York USA
105
days
Relationship between bisphosphonate use and risks of recurrence and mortality among hormone receptor–positive and triple‐negative breast cancer patients
AuthorsLiuye Huang; Linda S. Cook; Mei‐Tzu C. Tang; David R. Doody; Ulrike Peters; Wei Sun; Jeroen R. Huyghe; Kathleen E. Malone; Christopher I. Li
Affiliations1. Public Health Sciences Division Fred Hutchinson Cancer Center Seattle Washington USA; 2. Department of Epidemiology University of Washington Seattle Washington USA; 3. Department of Epidemiology University of Colorado‐Anschutz Aurora Colorado USA; 4. Department of Biostatistics University of Washington Seattle Washington USA
191
days
Assessment of safe chemotherapy handling behaviors among oncology nurses in a conflict‐affected setting: A cross‐sectional study from Gaza
AuthorsAbed El‐Rahman Rizq Mohammed Diab; Yousef Ibrahim Aljeesh
Affiliations1. Médecins du Monde France Gaza Palestine; 2. Faculty of Nursing The Islamic University of Gaza Gaza Palestine
213
days
Sexual health behaviors and contraceptive practices among Canadian childhood, adolescent, and young adult cancer survivors and controls
AuthorsIsmay A. E. de Beijer; Selina R. van den Oever; Oluwaseyi A. Lawal; Amanda Button; Jenny Duong; Heide Adham; Jennifer Giles; Kathleen Reynolds; Fiona S. M. Schulte
Affiliations1. Division of Psychosocial Oncology Cumming School of Medicine University of Calgary Arthur J.E. Child Comprehensive Cancer Centre Calgary Alberta Canada; 2. Long Term Survivor Clinic Trican Hematology/Immunology Oncology Blood and Marrow Transplant Program Alberta Children's Hospital Calgary Alberta Canada; 3. Department of Family Medicine Cumming School of Medicine University of Calgary Calgary Alberta Canada
74
days
Hypofractionated preoperative radiotherapy for extremity soft tissue sarcoma: Are we racing ahead of the toxicity data?
AuthorsKilian E. Salerno; Denise Reinke; Kathrin Schuster; B. Ashleigh Guadagnolo
Affiliations1. Radiation Oncology Branch National Cancer Institute Bethesda Maryland USA; 2. Sarcoma Patient Advocacy Global Network (SPAGN) Wölfersheim Germany; 3. Department of Radiation Oncology The University of Texas MD Anderson Cancer Center Houston Texas USA
237
days
Early neural signatures of cancer‐related fatigue: A longitudinal magnetic resonance imaging study of cortical micro‐ and macrostructural changes during breast cancer chemotherapy
AuthorsYanfei Zhou; Jin Liu; Xiao Fu; Jian Fan; Zong Cao; Jing Li; Ruiping Ye; Hongzhi Wang; Lizhuang Yang; Hai Li
Affiliations1. University of Science and Technology of China Hefei China; 2. Hefei Cancer Hospital of CAS Institute of Health and Medical Technology Hefei Institutes of Physical Science Chinese Academy of Sciences Hefei China; 3. Department of Radiology The First Affiliated Hospital of Anhui Medical University Hefei China; 4. Department of Breast Center Hefei Cancer Hospital Chinese Academy of Sciences Hefei China
41
days
Where does histotripsy fit into hepatocellular carcinoma care?
AuthorsKelsey S. Lau‐Min; Jiping Wang
Affiliations1. Division of Hematology/Oncology Department of Medicine Mass General Brigham Cancer Institute and Harvard Medical School Boston Massachusetts USA; 2. Division of Surgical Oncology Department of Surgery Mass General Brigham and Harvard Medical School Boston Massachusetts USA
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days